AIM: To evaluate the effect of Ahmed glaucoma drainage valve implantation and leizumab on neovascularization glaucoma.

METHODS: Totally 80 patients(80 eyes)of neovascularization glaucoma(NVG)according to random number table method were divided into 34 cases(34 eyes)of control group and 46 cases(46 eyes)of research group, the control group was treated with Ahmed glaucoma drainage valve implantation, the research group was treated with Ahmed glaucoma valve implantation combined with rezuzumab, clinical curative effect, cytokines, intraocular pressure, vision after 6mo, and complications in both group were compared.

RESULTS: Six months after surgery, the total success rate of operation in the research group was higher than that in the control group(P<0.05). 4d before surgery, there were no significant differences in intraocular pressure between the two groups(P>0.05). 7d after surgery, intraocular pressure in both groups all decreased, and the research group was lower than that in the control group(P<0.05). 6mo after surgery, the improvement rate of vision in the research group was higher than that in the control group(P<0.05). Within 6mo of follow-up, the drainage tube obstruction and hyphema rate in the research group were lower than those in the control group(P<0.05). There was no difference in corneal edema, anterior chamber exudation, eyeball pain, shallow anterior chamber and low intraocular pressure rate between the two groups(P>0.05).

CONCLUSION:Ahmed glaucoma drainage valve implantation combined with rezumab injection can reasonably control intraocular pressure and improve visual function of patients. It is a safe and effective treatment scheme for NVG patients.